Abstract
Central to the initiation of a T cell dependent immune response is the recognition of major histocompatibility complex (MHC) class I or class II molecules (in humans termed HLA and in mice termed H-2) bound to antigenic peptide. T cell receptors (TCR) have programmed specificity for particular peptide/MHC complexes, which ensures focused immune responses are generated against the antigen source. To design effective peptide based vaccines a comprehensive understanding of the specific interactions between MHC molecules and peptide, and of TCR recognition of MHC/peptide is valuable. We place particular emphasis on non-canonical bound peptides and their use in immunotherapy studies.
Keywords: Non-canonical peptides, MHC class I, vaccine
Current Pharmaceutical Design
Title: Non-Canonical Peptides Bound to MHC
Volume: 15 Issue: 28
Author(s): Stephanie L. Day, Paul A. Ramsland and Vasso Apostolopoulos
Affiliation:
Keywords: Non-canonical peptides, MHC class I, vaccine
Abstract: Central to the initiation of a T cell dependent immune response is the recognition of major histocompatibility complex (MHC) class I or class II molecules (in humans termed HLA and in mice termed H-2) bound to antigenic peptide. T cell receptors (TCR) have programmed specificity for particular peptide/MHC complexes, which ensures focused immune responses are generated against the antigen source. To design effective peptide based vaccines a comprehensive understanding of the specific interactions between MHC molecules and peptide, and of TCR recognition of MHC/peptide is valuable. We place particular emphasis on non-canonical bound peptides and their use in immunotherapy studies.
Export Options
About this article
Cite this article as:
Day L. Stephanie, Ramsland A. Paul and Apostolopoulos Vasso, Non-Canonical Peptides Bound to MHC, Current Pharmaceutical Design 2009; 15 (28) . https://dx.doi.org/10.2174/138161209789105090
DOI https://dx.doi.org/10.2174/138161209789105090 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Adult Stem Cell Treatment for Central Nervous System Injury
Current Tissue Engineering (Discontinued) Alzheimers Disease and Non-Steroidal Anti-Inflammatory Drugs: Old Therapeutic Tools with Novel Mechanisms of Action?
Current Medicinal Chemistry - Central Nervous System Agents Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Advances in Research of Schiff-Base Metal Complexes as Potent Antioxidants
Current Medicinal Chemistry Members of CRF Family and their Receptors: From Past to Future
Current Medicinal Chemistry Pharmacological Inhibition of Hsp90 as a Novel Antitumor Strategy to Target Cytoarchitecture Through Extracellular Matrix Signaling
Medicinal Chemistry Subject Index to Volume 3
Current Drug Targets - CNS & Neurological Disorders Alzheimers Disease and n-3 Polyunsaturated Fatty Acids: Beneficial Effects and Possible Molecular Pathways Involved
Current Signal Transduction Therapy Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology
Current Medicinal Chemistry Copper and Heme-Mediated Abeta Toxicity: Redox Chemistry, Abeta Oxidations and Anti-ROS Compounds
Current Topics in Medicinal Chemistry Synthesis and Biological Activity of Unnatural Enediynes
Current Medicinal Chemistry Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
Current Cancer Drug Targets Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers
Current Topics in Medicinal Chemistry Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Antigenic Differences Between Normal and Malignant Cells as a Basis for Treatment of Intracerebral Neoplasms Using a DNA-Based Vaccine
Current Genomics Chemotherapy In Japanese Encephalitis: Are We There Yet?
Infectious Disorders - Drug Targets Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses
Current Drug Targets - CNS & Neurological Disorders Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets